Document:

EX-4.7

 Exhibit 4.7 

Form of Subordinated Note 

(FACE OF SECURITY) 
 [Each
Global Security shall bear substantially the following legend: 
 UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE
REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH
NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY. UNLESS THIS SECURITY IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”), TO THE ISSUER OR ITS AGENT FOR
REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY SECURITY ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR
TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN
INTEREST HEREIN.] 
 [If the Security has original issue discount for U.S. federal income tax purposes, insert tax legend: 

[FOR PURPOSES OF SECTIONS 1272 , 1273, and 1275 OF THE INTERNAL REVENUE CODE OF 1986, AS AMENDED
(“THE CODE”), THIS SECURITY IS BEING ISSUED WITH ORIGINAL ISSUE DISCOUNT. THE AMOUNT OF ORIGINAL ISSUE DISCOUNT (AS DEFINED IN SECTION 1273(A)(1) OF THE CODE AND TREASURY REGULATION
SECTION 1.1273-1(A)) WITH RESPECT TO THIS SECURITY IS                     , THE ISSUE DATE (AS DEFINED IN
SECTION 1275(A)(2) OF THE CODE AND TREASURY REGULATION SECTION 1.1273-2(A)(2)) OF THIS SECURITY IS
                    , THE ISSUE PRICE (AS DEFINED IN SECTION 1273(B) OF THE CODE AND TREASURY REGULATION SECTION
1.1273-2(A)) OF THIS SECURITY IS                     , AND THE YIELD TO MATURITY (AS DEFINED IN TREASURY
REGULATION SECTION 1.1272-1(B)) OF THIS SECURITY IS                     .] ] 

 FULCRUM THERAPEUTICS, INC. 

[ Title of Security ] 
  

			
	No. [    ]	  	CUSIP No.: [    ]
		  	[Common Code][ISIN]: [    ]
		  	[$    ]

 FULCRUM THERAPEUTICS, INC., a Delaware corporation (the “Issuer”, which term includes any successor
corporation), for value received promises to pay to [If the Security is a Global Security — CEDE & CO.][If the Security is not a Global Security —
                    ] or registered assigns, the principal sum of
                 on                 ,      (the “Maturity
Date”) [If the Security is to bear interest prior to maturity, insert—, and to pay interest thereon from                      or
from the most recent interest payment date to which interest has been paid or duly provided for, [semiannually in arrears on                     
and                      in each year], commencing
                ,      (each, an “Interest Payment Date”) at the rate of [    % per annum], until the principal hereof
is paid or made available for payment [If applicable insert—, and (to the extent that the payment of such interest shall be legally enforceable) at the rate of     % per annum on any overdue principal and on any
overdue installment of interest]. The interest so payable, and punctually paid or duly provided for, on any Interest Payment Date will, as provided in the Indenture (as defined below), be paid to the Holder in whose name this Security (or one
or more predecessor Securities) is registered at the close of business on the record date for such interest, which shall be the                     
or                      (whether or not a Business Day), as the case may be, next preceding such Interest Payment Date (each, an “Interest
Record Date”). Interest will be computed on the basis of [a 360-day year of twelve 30-day months].] 

[If the Security is not to bear interest prior to maturity, insert—The principal of this Security shall not bear interest except
in the case of a default in payment of principal upon acceleration, upon redemption or at maturity and, in each such case, the overdue principal of this Security shall bear interest at the rate of     % per annum (to the
extent that the payment of such interest shall be legally enforceable), which shall accrue from the date of such default in payment to the date payment of such principal has been made or duly provided for. Interest on any overdue principal
shall be payable on demand.] 
 Reference is made to the further provisions set forth on the reverse of this Security contained herein,
which will for all purposes have the same effect as if set forth at this place. 

 IN WITNESS WHEREOF, the Issuer has caused this Security to be signed manually or by
facsimile by its duly authorized officer under its corporate seal. 
  

					
	FULCRUM THERAPEUTICS, INC.
		
	By:	 	  

		 	Name:	 	  

		 	Title:	 	  

 Attest: 
  

			
	 By:
	 	  

	 Name:
	 	  

	 Title:
	 	  

 This is one of the Securities of the series designated herein and referred to in the within-mentioned
Indenture. 
 Dated: [                    ] 

 

					
	                    
                    , as Trustee
		
	By:	 	  

		 	Title:	 	  

 (REVERSE OF SECURITY) 

FULCRUM THERAPEUTICS, INC. 
 [
Title of Security ] 
  

	1.	 Indenture. 

This Security is one of a duly authorized issue of debentures, notes or other evidence of indebtedness (hereinafter called the
“Securities”) of the Issuer of the series hereinafter specified, which series is initially limited in aggregate principal amount to [$]        , all of such Securities issued and to be issued
under an Indenture dated as of                     ,      (the “Indenture”) between the Issuer and
                     as trustee (the “Trustee”). Capitalized terms herein are used as defined in the Indenture unless otherwise
indicated. The terms of the Securities include those stated in the Indenture and those made part of the Indenture by reference to the Trust Indenture Act of 1939, as in effect on the date of the Indenture. The Securities are subject to all
such terms, and Holders are referred to the Indenture and the Trust Indenture Act for a statement of all such terms. To the extent permitted by applicable law, in the event of any inconsistency between the terms of this Security and the terms
of the Indenture, the terms of the Indenture shall control. 
 This Security is one of a series of Securities designated pursuant to the
Indenture [and a [Supplemental Indenture] dated                     ,     , issued pursuant to Section 2.01 and
Section 2.03 thereof (the “Supplemental Indenture”)] as                     . The Securities are general unsecured obligations of
the Issuer. The Issuer may, subject to the provisions of the Indenture and applicable law, issue additional Securities of any series under the Indenture. 
  

	2.	 Method of Payment. 

The Issuer shall pay interest on the Securities (except defaulted interest) to the persons who are the registered Holders at the close of
business on the Interest Record Date immediately preceding the Interest Payment Date notwithstanding any transfer or exchange of such Security subsequent to such Interest Record Date and prior to such Interest Payment Date. Holders must surrender
Securities to the Trustee to collect principal payments. The Issuer shall pay Principal and interest in money of [the United States] that at the time of payment is legal tender for payment of public and private debts. [However, the payments
of interest, and any portion of the Principal (other than interest payable at maturity or on any redemption or repayment date or the final payment of Principal) shall be made by the Paying Agent, upon receipt from the Issuer of immediately available
funds by      [a./p.m.], New York City time (or such other time as may be agreed to between the Issuer and the Paying Agent or the Issuer), directly to a Holder (by Federal funds wire transfer or otherwise) if the Holder
has delivered written instructions to the Trustee 15 days prior to such payment date requesting that such payment will be so made and designating the bank account to which such payments shall be so made and in the case of payments of principal
surrenders the same to the Trustee in exchange for a Security or Securities aggregating the same principal amount as the unredeemed principal amount of the Securities surrendered.] 

	3.	 Redemption. 

[The Securities of this series may be redeemed at any time [on or after
                    ,
                    ], as a whole or in part, at the option of the Issuer, upon mailing notice of such redemption not less than 30 and not
more than 60 days to the Holders of such Securities, at a redemption price equal to                     .] 

 

	4.	 Paying Agent and Security Registrar. 

Initially, the Trustee will act as Paying Agent and Security Registrar. The Issuer may change any Paying Agent or Security Registrar
without notice to the Holders. 
  

	5.	 Denominations; Transfer; Exchange. 

The Securities are in registered form, without coupons, in denominations of [$2,000] and multiples of [$1,000]. A Holder shall
register the transfer of or exchange Securities in accordance with the Indenture. The Issuer may require a Holder, among other things, to furnish appropriate endorsements and transfer documents and to pay certain transfer taxes or similar
governmental charges payable in connection therewith as permitted by the Indenture. [The Issuer need not register the transfer of or exchange (a) any Securities for a period of fifteen (15) days preceding the
first notice that such Securities are to be redeemed, or (b) any Securities selected, called or being called for redemption in whole or in part, except, in the case of any Security to be redeemed in part, the portion thereof not
to be so redeemed.] 
  

	6.	 Persons Deemed Owners. 

The registered Holder of a Security shall be treated as the owner of it for all purposes. 

 

	7.	 Unclaimed Funds. 

If funds for the payment of principal or interest remain unclaimed for two years, the Trustee and the Paying Agent will repay the funds to the
Issuer. After that, all liability of the Trustee and such Paying Agent with respect to such funds shall cease. 
  

	8.	 Defeasance. 

The Indenture [as amended by the Supplemental Indenture] contains provisions for defeasance at any time of (a) the entire
indebtedness of the Issuer on this Security and (b) certain restrictive covenants and the related Events of Default, upon compliance by the Issuer with certain conditions set forth therein, which provisions [apply] to this Security. 

 

	9.	 Amendment; Supplement; Waiver. 

Subject to certain exceptions, the Securities of this series, [the Supplemental Indenture] and the provisions of the Indenture relating to the
Securities of this series may be amended or supplemented with the written consent of the Holders of at least a majority in aggregate principal amount of the Securities of this series then outstanding, and any existing Default or Event of 

 
Default, other than the non-payment of the principal amount of or interest on the Securities of this series, or compliance with certain provisions may be
waived with the consent of the Holders of a majority in aggregate principal amount of all the Securities of this series, then outstanding. Without notice to or consent of any Holder, the parties thereto may amend or supplement the Indenture and the
Securities to, among other things, cure any ambiguity, defect or inconsistency, provide for uncertificated Securities in addition to or in place of certificated Securities, or make any other change that does not adversely affect the rights of any
Holder of a Security. 
  

	10.	 Defaults and Remedies. 

If an Event of Default (other than certain bankruptcy Events of Default with respect to the Issuer) occurs and is continuing, the Trustee or
the Holders of at least 25% in aggregate principal amount of Securities of this series then outstanding (voting as a separate class) by notice in writing to the Issuer (and also to the Trustee if such notice is given by the Holders) may declare
[the entire principal] of the Securities of this series and the interest accrued thereon, if any, to be due and payable immediately in the manner and with the effect provided in the Indenture. If a bankruptcy Event of Default with respect to
the Issuer occurs and is continuing, then [the entire principal] of the Securities then outstanding and interest accrued thereon, if any, shall become automatically due and payable immediately in the manner and with the effect provided in the
Indenture. Holders of Securities may not enforce the Indenture or the Securities except as provided in the Indenture. The Trustee is not obligated to enforce the Indenture or the Securities unless it has received indemnity satisfactory to it.
The Indenture permits, subject to certain limitations therein provided, Holders of a majority in aggregate principal amount of the Securities then outstanding to direct the Trustee in its exercise of any trust or power. The Trustee may withhold from
Holders of Securities notice of certain continuing Defaults or Events of Default if it determines that withholding notice is in their interest. 
  

	11.	 Subordination. 

Reference is made to the Indenture, including, without limitation, provisions subordinating the payment of principal of and premium, if any,
and interest on the Securities to the prior payment in full of all Senior Indebtedness as defined in the Indenture. Such further provisions shall for all purposes have the same effect as though fully set forth at this place. 

 

	12.	 Trustee Dealings with Issuer. 

The Trustee under the Indenture, in its individual or any other capacity, may become the owner or pledgee of Securities and may otherwise deal
with the Issuer as if it were not the Trustee. 
  

	13.	 No Recourse Against Others. 

No stockholder, director, officer, employee or incorporator, past, present or future as such, of the Issuer or any predecessor or successor
corporation thereof shall have any liability for any obligation under the Securities or the Indenture or for any claim based on, in respect of or by reason of, such obligations or their creation. Each Holder of a Security by accepting a Security
waives and 

 releases all such liability. The waiver and release are part of the consideration for the issuance of the
Securities. 
  

	14.	 Authentication. 

This Security shall not be valid until the Trustee manually signs the certificate of authentication on this Security. 

 

	15.	 Abbreviations and Defined Terms. 

Customary abbreviations may be used in the name of a Holder of a Security or an assignee, such as: TEN COM (= tenants in common), TEN ENT (=
tenants by the entireties), JT TEN (= joint tenants with right of survivorship and not as tenants in common), CUST (= Custodian), and U/G/M/A (= Uniform Gifts to Minors Act). 
  

	16.	 CUSIP Numbers. 

Pursuant to a recommendation promulgated by the Committee on Uniform Security Identification Procedures, the Issuer has caused CUSIP numbers to
be printed on the Securities as a convenience to the Holders of the Securities. No representation is made as to the accuracy of such numbers as printed on the Securities and reliance may be placed only on the other identification numbers printed
hereon. 
  

	17.	 Governing Law. 

The laws of the State of New York shall govern the Indenture and this Security thereof, and for all purposes this Security shall be governed by
and construed in accordance with the laws of such State without regard to any principle of conflict of laws that would require or permit the application of the laws of any other jurisdiction, except as may otherwise be required by mandatory
provisions of law. 

 ASSIGNMENT FORM 

I or we assign and transfer this Security to 
  

	
	
	  
 (Print or type name,
address and zip code of assignee or transferee)

	
	
	  
 (Insert Social
Security or other identifying number of assignee or transferee)

 and
irrevocably appoint                     
                     agent to transfer this Security on the books of the Issuer. The agent may substitute another to act for him. 

 

							
	Dated:	 	  
	 	Signed:	 	  

		 		 		 	(Signed exactly as name appears on the other side of this Security)
				
	 Signature
	 		 		 	
	 Guarantee:
	 	  
	 		 	
		 	Participant in a recognized Signature Guarantee Medallion Program (or other signature guarantor program reasonably acceptable to the Trustee)EXHIBIT 10.1

    

     

    

    

    SETTLEMENT AGREEMENT AND RELEASE

     

    

    

    This Settlement Agreement and Release (“Agreement”) is dated as of August 10, 2020 (the “Effective Date”), by and between STRATA SKIN SCIENCES, INC.
      (“Strata”), URI GEIGER (“Geiger”), and ACCELMED GROWTH PARTNERS, L.P. (“Accelmed”) (Strata, Geiger, and Accelmed will collectively be referred to as the “Strata Parties”), on the one hand, and RA MEDICAL SYSTEMS, INC. (“Ra Medical”), on the other
      (the Strata Parties and Ra Medical will collectively be referred to as the “Settling Parties”).

     

    RECITALS

     

    WHEREAS, Ra Medical caused its counsel at the law firm of Wingert Grebing Brubaker & Juskie to issue a certain cease and desist demand
      (the “Cease and Desist Letter”) dated August 22, 2018 to be issued to Strata;

     

    WHEREAS, on or about August 30, 2018, in response to the Cease and Desist Letter Strata and Geiger initiated a certain declaratory action
      captioned Strata Skin Sciences, Inc. and Uri Geiger v. Ra Medical Systems, Inc., civil action no. 18-21421, Court of Common Pleas, Montgomery County, Pennsylvania (the “Pennsylvania Action”), seeking, among
      other things, a declaratory judgment that Strata and Geiger had no liability to Ra Medical for the assertions and potential claims set forth in the Cease and Desist Letter;

     

    WHEREAS, on or about May 16, 2019, Ra Medical initiated a certain action captioned Ra Medical Systems, Inc.
        v. Uri Geiger, Strata Skin Sciences, Inc., and Accelmed Growth Partners, L.P., civil action no. 3:19-cv-00920, United States District Court for the Southern District of California (the “California Action”) (the Pennsylvania Action and the
      California Action will collectively be referred to as the “Pending Lawsuits”), asserting, among other things, that the Strata Parties were liable to Ra Medical in damages for certain activity pursuant to applicable law and a prior settlement
      agreement between Ra Medical and PhotoMedex, Inc.;

     

    WHEREAS, the Settling Parties have determined that it is in their best interest to terminate the Pending Lawsuits, with prejudice, but
      without any admission of liability, except for any obligations acknowledged and/or created or excluded by this Agreement and release each other from any claims that were or could have been asserted relating to the allegations therein which have
      arisen prior to the full execution of this Agreement;

     

    NOW, THEREFORE, in consideration of the foregoing premises and the agreements, terms, and provisions contained herein, and for other good and
      valuable consideration, the receipt of which is hereby acknowledged, the Settling Parties, intending to be legally bound, hereby agree as follows:

     

    1. Incorporation

            of Recitals.  The foregoing recitals are incorporated and made a part of this Agreement as though set forth in full.

     

    
      
        

        

        

      

      1

      
        

      

    

    

    

    2. Releases.

     

    (a) Release

          by the Strata Parties.  The Strata Parties, in consideration of the obligations set forth herein, hereby release Ra Medical, its affiliates, subsidiaries, divisions, successors,
        assigns, agents, representatives, employees, officers, and directors (collectively, the “Ra Medical Releasees”) from any and all claims, demands, and causes of action of any kind whatsoever, whether known or unknown, fixed or contingent, asserted
        or unasserted, arising in contract, tort, statute, or operation of law, which they now have or ever had against any of the Ra Medical Releasees, from the beginning of time to the date of the Agreement, in any way arising from or relating to the
        allegations, claims, causes of action, allegations and/or assertions set forth in the Pending Lawsuits.

     

    (b) Release

          by Ra Medical.  Ra Medical, in consideration of the obligations set forth herein, hereby releases the Strata Parties, and their affiliates, subsidiaries, divisions, successors, assigns, agents, representatives, employees, officers, and
        directors (collectively, the “Strata Parties Releasees”) from any and all claims, demands, and causes of action of any kind whatsoever, whether known or unknown, fixed or contingent, asserted or unasserted, arising in contract, tort, statute, or
        operation of law, which it now has or ever had against any of the Strata Parties Releasees, from the beginning of time to the date of the Agreement, in any way arising from or relating to the allegations, claims, causes of action, allegations
        and/or assertions set forth in the Pending Lawsuits.

     

    (a) In giving the aforementioned
        releases, which include claims that might be unknown or unsuspected at present, the Settling Parties represent, warrant, and agree that they have been fully advised by their attorneys of the contents of Section 1542 of the Civil Code of the State
        of California. The Settling Parties expressly waive and relinquish all rights and benefits under that section and any similar statute or common law principle of similar effect of any state or territory of the United States with respect to the
        aforementioned releases.  Section 1542 reads as follows:

     

    “A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing
      the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.”

     

    3. Stipulations

            of Dismissal.  Within 5 business days of the complete and final execution of this Agreement, the Settling Parties shall file stipulations and/or documentation necessary to cause each of the Pending Lawsuits to be dismissed with
        prejudice, with each party to bear its own attorneys’ fees and costs.  Except for claims resulting from an alleged breach of this Agreement, the Settling Parties covenant and agree not to file or prosecute any claim based upon matters within the
        scope of the general releases contained in Paragraph 2, supra.

     

    4. Representation

            by Counsel.  All parties to this Agreement acknowledge that they (i) have been represented by counsel in negotiating this Agreement; (ii) have read, and understand all of the terms and conditions of this Agreement and the
        consequences thereof; (iii) have knowingly and voluntarily entered into this Agreement; and (iv) have initiated no legal

     

    
      
        

        

        

      

      2

      
        

      

    

     

    

     

    proceedings related to the instant dispute other than the Pending Lawsuits. The Settling Parties hereby forever waive and relinquish any right or claim whatsoever to directly or collaterally attack the
      validity of this Agreement on any grounds.

     

    5. Interpretation

            of Agreement.  The Settling Parties agree that the terms of this Agreement are the product of informed negotiations, and that no presumption shall arise in the interpretation of the Agreement based upon the identity of the party that
        drafted any provision hereof. Accordingly, the normal rule of construction/contract interpretation to the effect that any ambiguities are to be resolved against the drafting party will not be employed in any interpretation of this Agreement.

     

    6. Severability. 

        If any provision of this Agreement or the application of any provision herein to any person or circumstance is held invalid or unenforceable only that provision shall be affected, and the remainder of this Agreement shall remain in full force and
        effect.

     

    7. Non-Waiver. 

        The delay or failure to enforce or seek enforcement of any right under this Agreement shall not constitute or be construed as (i) a waiver of such rights; (ii) a waiver of any remedy to enforce such rights; or (iii) acquiescence in any default.

     

    8. Binding

            Effect.  This Agreement shall be binding upon and inure to the benefit of the Settling Parties and their respective affiliates, successors, and assigns.  Other than the Ra Medical Releasees and the Strata Parties Releasees to the
        extent set forth in Sections 2(a) and 2(b) above, there are no third‐party beneficiaries of this Agreement, and nothing contained herein shall be deemed a release, waiver or modification in any manner or to any extent whatsoever of any claims,
        rights or remedies which any party to this Agreement has or may have against any person other than the parties to this Agreement, all of which claims, rights and remedies as against such non‐parties are expressly reserved.

     

    9. Agreement

            Governed By Pennsylvania Law.  This Agreement shall in all respects be interpreted, enforced and governed exclusively under the internal laws of the Commonwealth of Pennsylvania (without regard to its conflict of law provisions.

     

    10. Counterparts. 

        This Agreement may be signed in counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.  Delivery of an executed counterpart of a signature page to this Agreement
        by facsimile or electronic transmission (including in “ PDF” or similar format) shall be effective as delivery of a manually executed signature page hereto.

     

    11. Entire

            Agreement.  This Agreement constitutes the complete understanding between the Settling Parties concerning all matters relating to this matter and supersedes all prior discussions, agreements and understandings, both written and oral,
        between the parties with respect thereto and may not be modified other than by a written document, executed by all parties hereto.

     

    12. Execution

            of Documents to Effectuate Intent of Agreement.  The Settling Parties agree to execute without further consideration any and all further documents that may be necessary to effectuate the intent of this Agreement.

     

    
      
        

        

        

      

      3

      
        

      

    

     

    

     

    13. Authority

            to Settle.  The Settling Parties warrant and represent that they have collectively all of the interest in any of the matters set forth herein and that they have the full right, power, and specific authority to enter into, execute and
        consummate this Agreement.

     

    14. Confidentiality. 

        The parties hereto agree to keep the terms of this Agreement and the settlement as confidential, and shall not to disclose the terms of this settlement to anyone except (a) to their attorneys, accountants and auditors, (b) as required for
        governmental regulatory or compliance purposes, (c) to comply with any duly-served subpoena or discovery request in any legal proceeding, or (d) as otherwise required by law by law or a court order; provided, however, that nothing set forth in this
        paragraph shall prohibit any party hereto from disclosing this Agreement to enforce its terms or from stating that the parties have amicably settled the pending disputes among them.

     

    15. Headings.  All headings and captions in this Agreement are for convenience of reference only.  They shall not be deemed part of this Agreement and shall in no way define, limit, extend or describe the scope or intent of any
        provisions hereof.

     

    [Signature page follows.]

     

    
      
        

        

        

      

      4

      
        

      

    

    
    IN WITNESS WHEREOF, each Party has caused this Agreement to be executed as of the date first appearing above.

     

    

    

     

    STRATA SKIN SCIENCES, INC.

    

    

    

    

    By: /s/ Dolev Rafaeli                                       

        

    Name: Dolev Rafaeli

    Title: Chief Executive Officer

    

    

    

    

    

    

    URI GEIGER

    

    

    

    

       /s/ Uri Geiger                                               

        

    

    

    

    

    

    

    ACCELMED GROWTH PARTNERS, L.P.

    

    

    

    

    By: /s/ Uri Geiger                                             

        

    Name: Uri Geiger

    Title: Managing Partner

    

    

    

    

    

    

    

    RA MEDICAL SYSTEMS, INC.

    

    

    

    

    By: /s/ Daniel Horwood                                  

        

    Name: Daniel Horwood

    Title:  General Counsel

    

    

    
      

      

      

    

    

    

  5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}]]